Dose Optimization in Drug Development

edited by
Rajesh Krishna
Merck & Co., Inc.
Rahway, New Jersey, U.S.A.
Contents

Foreword Barry J. Gertz v
Preface vii
Contributors xiii

1. Introduction to Dose Optimization in Drug Development 1
   Rajesh Krishna
   Introduction 1
   Changing Face of Regulatory Environment 2
   New Technologies for Drug Development 4
   Risk Versus Benefit Assessment 8
   Implications on Dose Optimization 10
   References 10

2. Bridging Preclinical and Clinical Development: Disease Progression Modeling in Translational Research 15
   Paolo Vicini
   Introduction 15
   Biomarkers and Disease Progression Modeling 17
   A Role for Informatics and Computational Biology 18
   Finding and Validating Model-Based Biomarkers 20
   Conclusion 28
   References 29

3. Bridging Preclinical and Clinical Development: Biomarker Validation and Qualification 35
   John A. Wagner
   Introduction 35
   Definitions 37
   Validation and Qualification 39
Application of Validation and Qualification to
  Selected Biomarkers 42
Summary 43
References 43

4. Dose Selection for First-in-Human (FIH) Trials—Regulatory
  Perspective 45
Lois M. Freed
Introduction 45
Approach for Selecting the MRSD for
  FIH Trials of NMEs in Adult Healthy Volunteers 46
Basis for CDER’s Approach for Selecting a Maximum
  Safe Starting Dose for FIH Trials in Healthy Volunteers 47
Validation 52
Alternative Approaches to Estimation of MRSD
  for FIH Trial in Healthy Volunteers 53
Survey of Industry Approaches 55
Conclusions 56
References 57

5. Novel Clinical Trial Designs in Clinical Pharmacology and
  Experimental Medicine 61
Rajesh Krishna and James Bolognese
Introduction 61
Conventional Designs 62
Impetus for Novel Designs 66
Modeling and Simulations for Clinical Trial Designs 75
Summary 79
References 79

6. Biomarkers, Surrogate Endpoints, and Clinical Endpoints
  in the Development of Cardiovascular Drugs:
  A Regulatory Perspective 85
Peter H. Hinderling and Patrick J. Marroum
The Current Paradigm of Drug Development 85
Drug Response Measures 86
Acceptable Surrogate Endpoints and Biomarkers
  for Demonstrating Efficacy or Assessing the
  Toxic Potential of Drugs 87
Acceptable Biomarkers When Efficacy and Safety
  Are Established by Other Data 88
Relevance of and Current Issues with Biomarkers 90
Appendix 93
References 94
7. PK and PD Variability—Estimation and Appraisal of Its Impact on Dose Optimization with an Example of Gender Differences

Vladimir Piotrovsky

Introduction ........ 97
Mechanistic Consideration ........ 100
Population Modeling: Statistical Framework ........ 104
PK Differences Between Males and Females ........ 110
Gender Differences in PD and Clinical Endpoints ........ 122
Pitfalls in Estimating and Interpreting Effects of Subject Demographics ........ 130
Population Modeling and Simulation as a Tool for Dose Optimization in Drug Development ........ 132
Conclusion ........ 142
References ........ 143

8. Pharmacogenetics (PGx) and Dose Response: Dose Individualization

Wolfgang M. Schmidt and Markus Müller

Summary ........ 159
Introduction ........ 160
PGx, Drug Dose, and Safety ........ 163
PK and Drug Metabolism ........ 170
PD and Drug Efficacy ........ 174
Pharmacogenomics, Expression Signatures, and Predictive Biomarkers ........ 175
Current Challenges ........ 181
Outlook ........ 184
Conclusion ........ 185
References ........ 185

9. Optimal Dose Finding in Drug Development: Approaches and Regulatory Perspectives

Jogarao V. S. Gobburu and Mathangi Gopalakrishnan

Introduction ........ 195
Nomenclature ........ 196
Current Legal Requirements and Regulatory Expectations ........ 196
The Need for Better Dose-Finding Studies ........ 197
Approaches for Finding Optimal Dose ........ 200
Future Considerations ........ 210
References ........ 212
10. **Optimal Dose Selection in Drug Development: Role of Population Pharmacokinetics in Phase III** ........................................ 217
   *Willi Weber and Diether Rueppel*
   
   **Introduction** .... 217
   **The Learning and Confirming Concept** .... 219
   **Development of a Cardioprotective Drug** .... 222
   **Conclusion** .... 243
   **Appendix** .... 244
   **References** .... 245

11. **Dose Optimization Strategy for Strattera®, a CYP2D6 Substrate** ........................................ 247
    *Jennifer W. Witcher, Stephan Chalon, and John-Michael Sauer*
    
    **Introduction** .... 247
    **Background** .... 248
    **PK and Metabolism, Influence of Pharmacogenetics** .... 248
    **Development Strategy for a CYP2D6 Substrate** .... 251
    **Efficacy and Safety Studies** .... 253
    **Dose–Response and PK/PD Modeling** .... 254
    **Dosing Recommendations and Labeling** .... 255
    **References** .... 258

12. **Pediatric Dose Optimization Using Pharmacokinetics and Pharmacodynamics** ........................................ 261
    *Jun Shi*
    
    **Introduction** .... 261
    **General Considerations of PK/PD Study Design and Date Analysis in Pediatrics** .... 262
    **Population PK–PD of Sotalol in Pediatric Patients with Supraventricular or Ventricular Tachyarrhythmia** .... 266
    **Population PK of the Active Metabolite of Leflunomide in Pediatric Subjects with Polyarticular-Course Juvenile Rheumatoid Arthritis** .... 274
    **Conclusion** .... 283
    **References** .... 284

   **Index** .... 287